News Category: Uncategorized

CARLSBAD, Calif., March 6, 2020 – CarnoSyn^® Brands, a division of Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), and one of the world’s leading sports performance ingredients, has partnered with TEST Football Academy for the third year in a row to fuel NFL hopefuls in their preparation for the combine and their respective collegiate pro days. Several new Team CarnoSyn^® athletes made their mark at the 2020 NFL Scouting Combine.

TEST Football Academy is one of the nation’s top authorities in preparing college football players for the biggest job interview of their lives at the NFL Combine. The 2020 class consisted of 56 athletes—the largest class ever—who underwent an intensive 45-day program, which included a strict training, nutrition, and supplementation regimen, incorporating daily doses of both CarnoSyn^® instant release and SR CarnoSyn^® sustained release beta-alanine, via Kaged Muscle’s line of products.

The most powerful transformations in TEST’s 21-year history have been realized in the past three years, which are strongly attributed to the supplementation with CarnoSyn^® and SR CarnoSyn^®. In just 45 days, the 2020 TEST Combine class of 56 have undergone a metamorphosis—46 of which have resulted in a total fat loss of 216 pounds and a total lean body mass (LBM) gain of 257 pounds—for a total body composition swing of 473 pounds. Of the 46 athletes post-tested to date, this averaged 4.7 pounds of fat loss and 5.6 pounds of LBM gain, with an average total swing of 10.3 pounds. In terms of performance increases, TEST athletes have achieved an average increase of 2.5 inches on the vertical leap, 6 inches on the broad jump, 6 reps on the 225 bench press, and decreased 40 yard dash times by .17 seconds.

“We are very proud of the results of our partnership with TEST and Kaged Muscle^®—the athlete before and after photos provide a robust case study on how a well-designed training and supplementation program can truly transform the body,” said Ken Wolf, President and COO for Natural Alternatives International, Inc. “NAI has invested heavily in scientific research and stringent quality control over the years and the hard work has paid off.

CarnoSyn^® is the only beta-alanine that has successfully obtained NDI and self-affirmed GRAS status. Our growing list of awards and certifications, such as the 2019 Sports Nutrition Ingredient of the Year award from NutraIngredients-USA, have helped to establish CarnoSyn^® as a trusted brand and the only choice for tested, patented, and pure beta-alanine. We look forward to watching our sponsored athletes achieve their professional football dreams over the coming year.”

Kevin Dunn, TEST Football Academy Owner and CEO stated, “We are thrilled to continue our partnership with CarnoSyn^® and Kaged Muscle^®, who offer proven and banned substance-free products recognized by Informed Sport, Informed Choice, and Aegis Shield, which solidifies the fact that we’re providing the very best supplementation program available for our players that guarantees quality, potency and purity. Only CarnoSyn^® offers the patented, non-adulterated version of beta-alanine which accelerates muscle growth, increases strength and endurance by buffering lactic acid. We can’t risk using sub-standard products when so much is on the line for these athletes—those trying to go pro and every high school and college athlete competing for an athletic scholarship.”

“Every year we are blown away with the results of the TEST athletes,” said Brian Rand, Chief Innovation Officer at Kaged Muscle^®. “Not only can you visually see the muscle gains and fat loss, the athletes also experienced significant improvements on the field in speed, agility, endurance and strength by following an intense training protocol combined with premium supplements. Each athlete supercharged their performance by taking Kaged Muscle^®’s pre-workout, Pre-Kaged^®, our intra-workout, In-Kaged^®, and Re-Kaged^®, our post-workout, providing 3.2g of patented CarnoSyn^® beta-alanine. The athletes maximized their beta-alanine levels by stacking with our standalone sustained release SR CarnoSyn^® tablets and supplementing multiple times per day, leading to a total daily dosage of 9.6-11.2g of CarnoSyn^® and SR CarnoSyn^® combined. It’s important that athletes fuel their bodies with proven ingredients backed by science and why Kaged Muscle^® only uses CarnoSyn^® beta-alanine in our premium supplements.”

As part of the partnership, CarnoSyn^® Brands is sponsoring three players from the 2020 TEST NFL Combine class and continued sponsorship of one player from the 2019 TEST class, chronicling their inspirational journeys to build brand awareness and foster education on the efficacious loading and dosing of CarnoSyn^® and SR CarnoSyn^® beta-alanine. The proven performance is evident by the before and after photos and the NFL Combine performance.

Introducing the 2020 Team CarnoSyn^® Roster:

Nate Stanley, Quarterback for Iowa Hawkeyes
(2020 TEST Combine Class Transformation: Fat Loss – 23 pounds, LBM Gain – 10 pounds, Total Swing—33 pounds)
At 6-4 and 240 pounds, Nate Stanley is the prototypical NFL quarterback with a strong arm and big frame. Stanley was a rock for the Hawkeyes offense, starting all 39 games in his final three seasons at Iowa. He ranks second all-time in Hawkeyes history for touchdown passes (68) and career passing yards (8,302). He was a proven winner in his biggest games, going 3-0 in three bowl games.

Stanley’s NFL Combine performance was highlighted by a 4.81 official 40 yard dash, setting a personal record that was nearly 2 tenths faster than his day one 40 time at TEST. Next up is his Pro Day at Iowa on March 23rd. Stanley is expected to be a mid-round selection in the 2020 NFL Draft.

 

 

Kyle Murphy, Offensive Lineman for Rhode Island Rams
(2020 TEST Combine Class Transformation: LBM Gain – 13 pounds)
Kyle Murphy is a versatile offensive line prospect. Murphy, a team captain at Rhode Island, was named second team Associated Press All-American and received first team All-Colonial Athletic Association honors after starting 12 games at left tackle as a senior. The 6-3, 316-pound Murphy anchored an offensive line that allowed just 2.17 sacks per game despite his team averaging a league-high 42 pass attempts per game.

Murphy’s performance at the NFL Combine likely intrigued teams looking at adding quality depth to their roster. He checked the box at every combine drill and dominated his positional work displaying a huge upside to all 32 teams, especially coming from the FCS conference. He is expected to participate in his Pro Day at Rhode Island on March 25th. Murphy is projected to be a Day 3 5-7 round selection at the 2020 NFL Draft.

 

 

Myles Hartsfield, Safety for Ole Miss Rebels
(2020 TEST Combine Class Transformation: Fat Loss – 9.5 pounds, LBM Gain – 6.5 pounds, Total Swing—16 pounds)
Myles Hartsfield was a four-year starter at Ole Miss, alternating between cornerback and free safety over 48 collegiate games. As a senior in 2019 he matched his 2018 season with 41 tackles. He also compiled 2.5 tackles for loss, a sack and an interception. Hartsfield trained with TEST every off season.

Despite not receiving an invitation to the NFL Combine, Hartsfield’s Pro Day testing numbers will likely be among the top 5 in every event. He will have a chance to showcase his talents at the Ole Miss Pro Day on March 25th.

 

 

Tuzar Skipper, Linebacker for Pittsburgh Steelers
(2019 TEST Combine Class Transformation: Fat Loss – 3.7 pounds, LBM Gain – 12.6 pounds, Total Swing—16.3 pounds)
A defensive end out of the University of Toledo in 2019, Skipper racked up 60 tackles, 8.5 sacks and 11.5 tackles for loss en route to third-team All-MAC honors. While preparing for his Pro Day at TEST Football Academy in 2019, Skipper began supplementing with CarnoSyn^® beta-alanine. At UT’s Pro Day in March, Skipper put up an astonishing 30 reps on the bench press—a total which would’ve ranked second among all edge defenders at the 2019 NFL Combine. He supplemented that spectacular feat of strength with a 10-foot-7 broad jump.

Skipper was initially an undrafted free agent for the Steelers who made Pittsburgh’s 53-man roster coming out of camp, but was waived shortly prior to their first regular-season game. The New York Giants proceeded to poach him off waivers, and he totaled 3 tackles and a half sack over his six games on their active roster. He was moved to their practice squad in late October, and the Steelers snatched him back to their own active roster, signing a two-year contract and cementing Skipper’s future in the NFL.

About CarnoSyn^® Brands:
CarnoSyn^® Brands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn^® instant release beta-alanine and SR CarnoSyn^® sustained release beta-alanine. In 2019, CarnoSyn^® beta-alanine successfully obtained NDI status from the FDA. In the sports nutrition segment, both ingredients are well known to deliver benefits for athletic performance: Increased strength, enhanced endurance, faster recovery and greater mental focus.

SR CarnoSyn^® is an advanced delivery form of CarnoSyn^®, which delivers higher dosing levels of beta-alanine, and is proven to provide benefits for both wellness and healthy aging. In 2017, SR CarnoSyn^® was determined to be safe through independent scientific procedures, thus satisfying the technical element of the Generally Recognized as Safe (GRAS) determination. The GRAS affirmation allows NAI to broaden their product offerings beyond the sports nutrition space and focus on the dietary supplement and food and beverage industries, including medical and other fortified food products.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

About TEST Football Academy:
TEST Football Academy has been training football players at all levels since 1999. Over that tenure, they have assembled the most experienced, world class team ever to prepare collegiate NFL prospects for the NFL Combine and Pro Days. They also work with youth and high school athletes, helping competitors of all ages get to the next level.

TEST Football Academy is the result of Owner and CEO, Kevin Dunn, Director of Football Operations, Geir Gudmundsen and a team professionals with over a century of collective experience, having worked with nearly 400 pro athlete hopefuls over two decades, with a success rate of over 250 athletes who have gone on to play professional football. In a savage pursuit of mastering the details, they have partnered up with 4X Olympic Sprint Medalist and NBC Sports Analyst Ato Boldon for intensive 40 yard dash work and Absolute Nutrition Solutions Owner, Lauren Dunn, who provides all the nutrition tools necessary to fuel the athlete’s transformations. Offensive coordinator & quarterback coach Tony Racioppi, has also quickly become one of the most sought out quarterback coaches in the country that includes a resume as a lead coach for the Manning Passing Camp for the past 7 years with 23 current professional quarterback’s and 24 current D1 quarterback’s. Finally, Robert Price from Elite Minds (former Sports Psychologist with the NY Giants) helps players master their interview prep and the mental side of peak performance. Collectively, they prepare players for the NFL Combine, Pro Days and help to extend NFL careers with consistent follow-up and coaching in the off season year after year. No longer does an athlete have to accept one trainer when they can have an entire team of experts supporting them on the most important journey of their lives with the potential to earn generational income.

About Kaged Muscle:
Kaged Muscle^® is an award winning, ultra-premium sports nutrition line and lifestyle brand, created to help athletes and fitness enthusiasts of all levels reach their transformation goals. Headquartered in Huntington Beach, California, KM is a rapidly growing producer of innovative, high-quality products in the sports nutrition category. Earning top accolades in 2017 and 2018 for their flagship products, Pre-Kaged^®, In-Kaged^® and Kasein^®, from sports nutrition retail giants Bodybuilding.com, GNC and Vitamin Shoppe, KM’s award-winning line has quickly become an industry leader for clean, premium quality products and the brand consumers can trust.

Formulated with research-backed premium quality and patented ingredients, each and every KM product undergoes rigorous in-lab development and testing as well as real-world use in the gym by top athletes, to ensure their quality and effectiveness. KM’s commitment to providing athletes of all levels with premium, safe, science-backed sports nutrition products sets the brand apart from many of its competitors. The comprehensive line of sports nutrition products is third party tested for purity and potency, contains no artificial colors or flavors, no synthetic caffeine, fermented and vegan-sourced amino acids, and is certified free of banned substances by Informed-Choice and Informed-Sport. In addition to offering premium quality products, KM also provides consumers with an array of powerful resources, including hundreds of articles, videos and online trainers, to help educate and guide them on their journey to better health and performance.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

###

SOURCE: Natural Alternatives International, Inc.

CONTACT:
Renee Michaelson, CarnoSyn^® Marketing Manager, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Websites: http://team.carnosyn.com/ and http://www.srcarnosyn.com/ and http://nai-online.com

CARLSBAD, Calif., Feb. 11, 2020 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $476,000, or $0.07 per diluted share.

Net sales during the three months ended December 31, 2019 decreased $6.9 million, or 19.3%, from $36.0 million recorded in the comparable prior year period.  During the same period, private-label contract manufacturing sales decreased $6.8 million, or 21.6%, from the comparable quarter last year. Second quarter contract manufacturing sales decreased primarily due to lower sales to our largest contract manufacturing customer.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 2.5% to $4.3 million during the second quarter of fiscal 2020, as compared to $4.4 million for the second quarter of fiscal 2019.

Net income for the three months ended December 31, 2019 was $476,000, or $0.07 per diluted share as compared to net income of $2.2 million, or $0.31 per diluted share in the second quarter of fiscal 2019.

Net income for the six months ended December 31, 2019 was $572,000, or $0.08 per diluted share, compared to net income of $4.7 million, or $0.68 per diluted share, for the six months ended December 31, 2018.

Net sales during the six months ended December 31, 2019 decreased $14.3 million, or 19.7%, from $72.6 million recorded in the comparable prior year period.  For the six months ended December 31, 2019, private label contract manufacturing sales decreased $11.9 million, or 19.0%, from the comparable period last year. Contract manufacturing sales for the first six months of fiscal 2020 decreased primarily due to lower sales to our largest customer partially offset by increased sales to other new and existing customers. Sales to our largest contract manufacturing customer declined over 31%.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue during the six months ended December 31, 2019 decreased $2.4 million, or 24.1%, from $9.8 million during the comparable period last year. We believe this decline was impacted by certain customers discontinuing the use of our CarnoSyn® beta-alanine in favor of generic beta-alanine and lower overall consumer demand for our customers’ CarnoSyn® products.  We expect the recent ruling from the U.S. Court of Appeals for the Federal Circuit in favor of NAI’s CarnoSyn® beta-alanine patents, along with our CarnoSyn® beta-alanine New Dietary Ingredient (NDI) status from the FDA, will help motivate buyers to purchase CarnoSyn® in the future.  We continue to vigorously pursue all legal avenues to protect our CarnoSyn® brands, intellectual property portfolios, and regulatory compliance status.

For the second half of fiscal 2020, as compared to the same period in the prior year, we expect sales levels to our largest contract manufacturing customer to decline 20% to 25% and our CarnoSyn® beta-alanine revenue to be comparable to the prior year. As a result, on an annualized basis, we now expect our consolidated fiscal 2020 revenue to decline approximately 10% to 15% as compared to the prior fiscal year.

As of December 31, 2019, NAI had cash of $26.9 million and working capital of $57.3 million compared to $25.0 million and $57.1 million, respectively, as of June 30, 2019.  As of December 31, 2019, we had $10.0 million available under our line of credit agreement.

Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, “The second quarter remained challenging, but our sales team and management continue to work diligently to secure additional opportunities given the continued right-sizing of inventory by our largest customer.”

“The marketplace has been challenging due to several factors, but we see signs of normalization appearing on the horizon as evidenced by renewed purchases from many of our customers who have been cautiously monitoring their inventory levels.”

“While sales to our largest contract manufacturing customer contracted in the past several quarters due to a variety of factors, we believe their sales will stabilize later this fiscal year and we will continue to expand our customer base through new customer acquisition and new product launches with existing customers.”

“We continue to seek to expand our footprint of CarnoSyn® and SR CarnoSyn® patented supplements, in addition to working with regulators to monitor and fully implement provisions leading to better consumer protections under applicable laws and regulations.”

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers.  Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information.  These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to introduce products in new sales channels, maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein.  NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Web site: http://nai-online.com

 

CARLSBAD, CA, January 29, 2020—Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), the company behind SR CarnoSyn^®, a patented, sustained-release beta-alanine, will exhibit at the Integrative Healthcare Symposium (IHS) Annual Conference in New York, NY on February 20-22, 2020 at the New York Hilton Midtown. The CarnoSyn^® Brands team will present the latest clinical research on their groundbreaking ingredient solution for healthy aging and everyday wellness during a luncheon session on Friday, February 21^st.

CarnoSyn^® Brands will be featured at booth #TT8—attendees will have the opportunity to learn about the science and strategy behind SR CarnoSyn^®.

“Our team is looking forward to meeting with healthcare practitioners during IHS and introducing them to the latest solutions available for improved health and wellness,” said Ken Wolf, President, NAI. “We offer healthcare practitioners a new way to help patients live their best life at any age with SR CarnoSyn®, the only beta-alanine supplement with New Dietary Ingredient status. We have much news to share with attendees, as 2019 was a monumental year for our CarnoSyn^® Brands. Not only were we recognized for major contributions to sports nutrition and science after winning NutraIngredients-USA’s 2019 Sports Nutrition Ingredient of the Year, but we were also honored to receive the 2019 Novel Ingredient and Science Award from the Natural Products Association.”

“Healthcare practitioners attend IHS to learn and collaborate on the latest insight and techniques related to holistic healthcare,” said Dr. Di Tan, Director of Scientific Affairs, CarnoSyn^® Brands. “I am excited to present news and clinical research about SR CarnoSyn^®, which is an incredible breakthrough in healthy aging and wellness. It offers five valuable benefits including brain, muscle, heart, bone and overall systemic support. This is a session attendees will not want to miss.”

Attendees can find out more about SR CarnoSyn^® at the IHS Conference:

• Lunch & Learn Session on Friday, February 21, 12pm – 1:30pm:
  Scientists Di Tan, Ph.D. and Jay Hoffman, Ph.D., FNSCA, FACSM will present “How SR CarnoSyn® Beta-Alanine Supplementation Supports Healthy Aging and Wellness.” The session will focus on the scientific studies regarding beta-alanine supplementation and its role in generating carnosine in the body to support overall systemic health, cognitive function and muscle function. The efficiency of SR CarnoSyn®’s patented delivery system will also be presented. Register for the event at https://www.ihsymposium.com/how-sr-carnosyn-beta-alanine-supplementation-supports-healthy-aging-and-wellness/.

Learn more about SR CarnoSyn^® beta-alanine by visiting IHS Booth #TT8 or see our latest video at www.srcarnosyn.com.

About CarnoSyn^® Brands:
CarnoSyn^® Brands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn^® instant release beta-alanine and SR CarnoSyn^® sustained release beta-alanine. In 2019, CarnoSyn^® beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status at up to 6.4 grams per day, enabling NAI’s brand partners to provide unique offerings in various food categories. In the sports nutrition segment, both ingredients are well known to deliver benefits for athletic performance: Increased strength, enhanced endurance, faster recovery and greater mental focus.

SR CarnoSyn^® is an advanced delivery form of CarnoSyn^®, which delivers higher dosing levels of beta-alanine, and is proven to provide benefits for both wellness and healthy aging. In 2017, SR CarnoSyn^® was determined to be safe through independent scientific procedures, thus satisfying the technical element of the GRAS determination. The GRAS affirmation allows NAI to broaden their product offerings beyond the sports nutrition space and focus on the dietary supplement and food and beverage industries, including medical and other fortified food products.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

CONTACT: Carrie Livingston
Director of Media Relations, Colin Kurtis
Email: [email protected]
Phone: 815-519-8302

CARLSBAD, Calif., Jan. 13, 2020 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced its Board of Directors authorized a $2.0 million increase to its stock repurchase plan bringing the total plan authorized repurchase amount to $9.0 million. Under the repurchase plan, NAI may, from time to time, purchase shares of its common stock, depending upon market conditions, in open market or privately negotiated transactions. Since September 30, 2019, we have purchased an additional 253,155 shares of our common stock under this plan bringing our total plan purchases to date to 1.1 million shares. At present there is $1.8 million remaining available for stock repurchases under the plan.

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our financial condition, and our ability to acquire our own shares on a reasonable basis, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or investor@nai- online.com.

Web site: http://nai-online.com/

CARLSBAD, Calif., Nov. 14, 2019 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $96,000, or $0.01 per diluted share, on net sales of $29.2 million for the quarter ended September 30, 2019.

Net sales during the three months ended September 30, 2019 decreased $7.3 million, or 20.1%, from $36.5 million recorded in the comparable prior year period.  During the same period, private-label contract manufacturing sales decreased $5.1 million, or 16.3%, from the comparable quarter last year. Sales to our largest private-label contract manufacturing customer declined over 33%, while sales to all other private-label contract manufacturing customers increased more than 23%, including sales of new products to new and existing customers.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 41.5% to $3.2 million during the first quarter of fiscal 2020, as compared to $5.4 million for the first quarter of fiscal 2019.  We believe this decline was impacted by certain of our customers discontinuing the use of our CarnoSyn® beta-alanine in favor of generic beta-alanine and lower overall consumer demand for our customers’ CarnoSyn® products.  We expect the recent ruling from the U.S. Court of Appeals for the Federal Circuit in favor of NAI’s CarnoSyn® beta-alanine patents, along with our CarnoSyn® beta-alanine New Dietary Ingredient (NDI) status from the FDA, will help motivate buyers to purchase CarnoSyn® in the future.  Additionally, we will continue to vigorously pursue all legal avenues to protect our CarnoSyn® brand, intellectual property portfolio, and regulatory compliance status, we have already brought some legal actions, and anticipate there will be others.

We currently expect annualized fiscal 2020 private-label manufacturing sales to be flat to slightly down as compared to fiscal 2019.  This estimate includes expectations of lower sales revenue from our largest private-label contract manufacturing customer.

Additionally, we currently expect CarnoSyn® and SR CarnoSyn® beta-alanine revenue growth in the mid-to high single digit percentage range during fiscal year 2020.  However, based on our strategy to defend our patents, trademarks, and NDI status for our CarnoSyn® brands, expand the Japanese marketplace for our CarnoSyn® brands, and increase marketing, advertising and promotion costs for our launch into the Wellness and Healthy Aging markets for SR CarnoSyn®, we anticipate operating income will be flat to slightly down in fiscal year 2020 as compared to fiscal year 2019.

As of September 30, 2019, NAI had cash of $28.5 million and working capital of $58.1 million compared to $25.0 million and $57.1 million, respectively, as of June 30, 2019.  As of September 30, 2019, we had $10.0 million available under our line of credit agreement.

Mark A. LeDoux, Chairman and Chief Executive Officer stated, “The sales cycle to generate new relationships in this industry is not brief, so the fact that we are generating new customers is a testament to our continued commitment to quality and partnership with our esteemed clientele.

“We intend to launch our new sustained release CarnoSyn® powder product, which is suitable for various finished product presentations, to the marketplace and we expect positive results from this introduction. We also continue to work with applicable government agencies to prevent introduction of adulterated goods into the marketplace that have not demonstrated profiles of safety.

“While the last several months have proved challenging, our balance sheet remains strong, with no debt and ample cash reserves allowing us to aggressively pursue new customers as we seek to continue to diversify our client and channel concentrations. Our team remains committed to overcoming these short-term challenges and increasing profitability.”

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers.  Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance.  For more information about NAI, please see our website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to introduce products in new sales channels, maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein.  NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Web site: http://nai-online.com

TUCSON, AZ, November 7-10, 2019—Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), the company behind SR CarnoSyn^®, a patented, sustained-release version of CarnoSyn^® beta-alanine, is showcasing several new ingredient solutions for healthy aging at the Age Management Medicine Group (AMMG) Conference in Tucson, AZ on November 7-10, 2019 at JW Marriott Tucson Starr Pass Resort & Spa.

CarnoSyn^® Brands will be exhibiting at booth #206 as they focus on the science and strategy around the most innovative ingredients in healthy aging and everyday wellness. Conference attendees are invited to visit the booth to learn more about these exciting new offerings.

“We are thrilled to meet with healthcare practitioners during AMMG and help them learn more about the latest clinical research behind SR CarnoSyn^® beta-alanine,” said Ken Wolf, President, NAI. “CarnoSyn^® Brands was recognized for major contributions to sports nutrition and science after winning NutraIngredients-USA’s 2019 Sports Nutrition Ingredient of the Year, and SR CarnoSyn^® is our latest groundbreaking ingredient. We also received the 2019 Novel Ingredient and Science Award from the Natural Products Association.”

“Healthcare practitioners come to AMMG seeking the latest insight and information for age management,” said Dr. Di Tan, Director of Scientific Affairs, CarnoSyn^® Brands. “New, sustained-release SR CarnoSyn^® is the breakthrough that patients deserve as it promotes healthy aging and wellness in five ways including brain function, muscle fitness, heart health, strong bones and overall systemic support. With SR CarnoSyn^®, we offer healthcare practitioners a new way to help patients live their best life at any age with the only beta-alanine with New Dietary Ingredient status. Multiple studies have shown that just 2.4 grams of SR CarnoSyn^® beta-alanine per day leads to increased carnosine levels in the body and better everyday wellness.”

SR CarnoSyn^® will be featured at several key areas during the AMMG event, including:

•  Booth #206 – stop by the Arizona Ballroom booth and connect with the team to learn more about their latest ingredient innovations
•  Lunch & Learn Session on Friday, 11/8 from 12:15pm – 1:15pm in the Tucson Ballroom:
“How SR CarnoSyn^® Beta-Alanine Supplementation Supports Healthy Aging Via Supporting Cognitive Function and Muscle Health”

Find out more about SR CarnoSyn^® beta-alanine by visiting AMMG Booth #206 or www.srcarnosyn.com.

About CarnoSyn^® Brands:
CarnoSyn^® Brands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn^® instant release beta-alanine and SR CarnoSyn^® sustained release beta-alanine. In 2019, CarnoSyn^® beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status at up to 6.4 grams per day, enabling NAI’s brand partners to provide unique offerings in various food categories. In the sports nutrition segment, both ingredients are well known to deliver benefits for athletic performance: Increased strength, enhanced endurance, faster recovery and greater mental focus.

SR CarnoSyn^® is an advanced delivery form of CarnoSyn^®, which delivers higher dosing levels of beta-alanine, and is proven to provide benefits for both wellness and healthy aging. In 2017, SR CarnoSyn^® was determined to be safe through independent scientific procedures, thus satisfying the technical element of the GRAS determination. The GRAS affirmation allows NAI to broaden their product offerings beyond the sports nutrition space and focus on the dietary supplement and food and beverage industries, including medical and other fortified food products.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

 

LAS VEGAS, Oct. 16, 2019 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), the company behind SR CarnoSyn^®, a patented, sustained-release version of beta-alanine, is showcasing several innovative ingredient solutions at the SupplySide West Tradeshow in Las Vegas, NV on October 17 and 18, 2019.

CarnoSyn^® Brands and Natural Alternatives International come together at SSW Booth #5851 as they focus on the science and strategy around the most innovative ingredients and solutions in the industry. Attendees are invited to visit the booth to learn more about these latest ingredient offerings.

“CarnoSyn^® Brands was recently recognized for its major contributions in sports nutrition and science when it was named 2019 Sports Nutrition Ingredient of the Year by NutraIngredients-USA and went on to receive the Novel Ingredient and Science Award from the NPA,” said Ken Wolf, President, NAI. “We’re looking forward to continued success at SupplySide West, informing the industry on our patented NDI status beta-alanine offerings in both sports nutrition and wellness.”

“We are especially proud to be exhibiting sustained -release SR CarnoSyn^®,” said Dr. Di Tan, Director of Scientific Affairs, CarnoSyn^® Brands. “It promotes healthy aging and wellness in five ways including brain function, muscle fitness, heart health, strong bones and overall systemic support. With SR CarnoSyn^® our customers can help consumers live their best life at any age with the only beta-alanine with NDI status. Multiple studies have shown that just 2.4 grams of SR CarnoSyn^® beta-alanine per day leads to increased carnosine levels in the body and better everyday wellness.”

SR CarnoSyn^® will be featured at several key areas during the SSW event, including:

•  SSW Booth #5851 – stop by the booth and connect with the team to learn more about their latest ingredient innovations
•  SSW Supplier Launch Pad Event – Thursday, 10/17 at 12:35pm
•  SSW Breakfast Brief – Friday, 10/18 from 9am-10am
•  SSW New Products Zone – Thursday and Friday of the show

Find out more by visiting SSW Booth #5851, srcarnosyn.com or carnosyn.com.

About CarnoSyn® Brands:
CarnoSyn^® Brands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn^® instant release beta-alanine and SR CarnoSyn^® sustained release beta-alanine. In 2019, CarnoSyn^® beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status at up to 6.4 grams per day, enabling NAI’s brand partners to provide unique offerings in sports nutrition, healthy aging and wellness and other food categories. SR CarnoSyn^® was also determined to be safe through independent scientific procedures, thus satisfying the technical element of the GRAS determination, and allowing NAI to focus on the broader dietary supplement and food and beverage industries, including medical and other fortified food products. SR CarnoSyn^® is an advanced delivery form of CarnoSyn^®, which delivers higher dosing levels of beta-alanine, and is proven to provide benefits for both wellness and healthy aging. These benefits include supporting brain function, muscles fitness, heart health, strong bones and overall systemic protection.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

CONTACT: Carrie Livingston
Email: [email protected]
Phone: 815-519-8302

CARLSBAD, Calif., Sept. 24, 2019 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today reported financial operating results for the fourth quarter and fiscal year ended June 30, 2019.

For the fiscal year 2019, net income was $6.5 million, or $0.92 per diluted share, on net sales of $138.3 million, compared to net income of $5.1 million, or $0.73 per diluted share, on net sales of $132.4 million for fiscal year 2018.

The previous period’s results were unfavorably impacted by one-time discrete tax expense amounts recorded in connection with the 2017 U.S. Tax Cuts and Jobs Act.  These one-time charges totaled $3.0 million, or approximately $0.44 per diluted share.  Excluding these discrete tax items, our adjusted net income during the fiscal 2018 was $8.1 million, or $1.17 per diluted share.

Net sales during fiscal year 2019 increased $5.9 million, or 4%, from $132.4 million recorded in the prior year.  For fiscal year 2019, private-label contract manufacturing sales increased $10.6 million, or 10%, from the comparable period last year. The increase was due primarily to the sale of new products to new and existing customers, and higher volumes of current products to existing customers located primarily in the U.S. and Asian markets. Sales to our largest private-label contract manufacturing customer decreased 8.3%, however, sales to all other private-label contract manufacturing customers increased more than 40%. The sales decline from our largest private-label contract manufacturing customer primarily related to reduced demand in their international operations. Their sales decline accelerated during the fourth quarter of fiscal year 2019 and resulted in lower product re-orders.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 22% to $16.7 million during fiscal year 2019 as compared to $21.4 million for fiscal year 2018. We believe this sales decline was impacted by certain customers discontinuing the use of our CarnoSyn® beta-alanine in favor of generic beta-alanine.  We expect the recent ruling from the U.S. Court of Appeals for the Federal Circuit in favor of NAI’s CarnoSyn® beta-alanine patents, along with our CarnoSyn® beta-alanine New Dietary Ingredient (NDI) status from the FDA, will help motivate departed brands and contract manufacturers to purchase CarnoSyn® in the future.  Additionally, we will continue to pursue all legal avenues to protect our CarnoSyn® brand, intellectual property portfolio, and regulatory compliance status.

Net sales during the three months ended June 30, 2019, decreased $9.0 million, or 23%, from $39.2 million recorded in the comparable prior year period.  For the quarter ended June 30, 2019, private label contract manufacturing sales decreased $6.7 million, or 20%, from the comparable quarter last year. Sales to our largest private-label contract manufacturing customer declined over 50%, however, sales to all other private-label contract manufacturing customer increased over 50%, including sales of new products to new and existing customers.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 42% to $3.2 million during the fourth quarter of fiscal year 2019, as compared to $5.4 million for the fourth quarter of fiscal 2018. We believe this sales decline was impacted by certain customers discontinuing the use of our CarnoSyn® beta-alanine in favor of generic beta-alanine.

We had a net loss of $0.2 million, or $0.03 per diluted share, for our fourth quarter of fiscal year 2019, compared to a net income of $2.9 million, or $0.41 per diluted share, in the fourth quarter of fiscal year 2018. This decrease was primarily attributable to a decrease in CarnoSyn® beta-alanine revenue, a one-time write off of $686,000 related to obsolete SR CarnoSyn® inventory, and increased legal and advertising expenses associated with our CarnoSyn® business, and decreased private-label contract manufacturing sales.

Given our planned business strategies, current currency headwinds and economic business trends, we expect private-label manufacturing sales growth in the low to mid- single digit percentage range in fiscal year 2020.  This estimate includes expectations of flat to slightly down sales revenue for our largest private-label contract manufacturing customer.

Additionally, we expect CarnoSyn® and SR CarnoSyn® beta-alanine revenue growth in the mid-to high single digit percentage range during fiscal year 2020.  However, based on our strategy to defend our patents, trademarks, and NDI status for our CarnoSyn® brands, the expansion of the Japanese marketplace for our CarnoSyn® brands, and increased marketing, advertising and promotion costs expected to be deployed for our launch into the Wellness and Healthy Aging markets for SR CarnoSyn®, we anticipate operating income will be flat to slightly down in fiscal year 2020 as compared to fiscal year 2019.

As of June 30, 2019, we had cash of $25.0 million and working capital of $57.1 million compared to $23.6 million and $50.9 million, respectively, as of June 30, 2018.  As of June 30, 2019, we had $10.0 million available under our line of credit agreement.

Mark A. LeDoux, Chairman and Chief Executive Officer stated, “This final quarter of our fiscal year was challenging as we navigated some customer and regional softening of demand, primarily in Europe, and addressed inventory valuation challenges. Our team was able to limit these negative impacts, while focusing on new opportunities and expanding our penetration of other regional growth markets. The industry is experiencing the deleterious impacts of international supply chain tariffs, regional regulatory demands, which are often arbitrary or capricious, and uncertainties about potentially arduous new standards for products.”

“While these market conditions exist in the short term, having a strong balance sheet with no debt and sound levels of liquidity provides us a haven in an unpredictable environment.  We continue to work with regulators globally to enforce statutory requirements, assuring product integrity with an ever vigilant eye to quality and safety of ingredients.”

“NAI was recently recognized by the venerable Natural Products Association for Innovation in Science, with its continued work in research surrounding CarnoSyn® and SR CarnoSyn® beta-alanine.  This award is a significant acknowledgment of NAI’s industry leadership, commitment to innovation, research and development, and our perseverance to go above and beyond, including achieving NDI status from the FDA for CarnoSyn® beta-alanine.”

“While our recent results have fallen short of our expectations, we remain committed to expanding our profitability in this fiscal year through attention to detail across all business units. Additionally, we will continue to align our supply chain requirements in the most cost and quality effective manner available to our world-class production teams in the USA and Switzerland. Finally, we are committed to industry leadership with a steadfast commitment to quality.”

Reconciliation of Non-GAAP Information

The GAAP results contained in this press release and the financial statement schedules attached to this press release have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).  In addition to the Company’s results prepared in accordance with GAAP, the Company provided information on a non-GAAP basis. The manner in which this non-GAAP information is derived is discussed below, and the Company has provided in the tables to this release a reconciliation of the non-GAAP information to the most directly comparable GAAP information.

Net (Loss) Income and EPS Adjusted for Non-Recurring Tax Expense. In order to make the fiscal year 2018 results comparable to fiscal year 2019, we have presented net income and EPS for the fiscal 2018 on a non-GAAP basis by excluding discrete tax items related to the 2017 U.S. Tax Cuts and Jobs Act for the quarter and year ended June 30, 2018.  The following is a schedule reconciling our Adjusted Net Income and EPS to our GAAP Net Income and EPS.

 

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers.  Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information.  These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, future acquisitions, revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein.  NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Web site: http://nai-online.com

 

CARLSBAD, Calif., Sept. 17, 2019 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII) today proudly announces its CarnoSyn^® beta-alanine has received the coveted Novel Ingredient and Science Award from the Natural Products Association (NPA) at their annual conference, The Big Natural, in Washington, D.C., held September 11-12, 2019.

The Novel Ingredient and Science Award is bestowed annually upon a person or company who has developed an innovative ingredient with far reaching applications, clinical disease utility, health benefit, or regulatory safety achievement, demonstrated through sound scientific research. The NPA recognizes NAI for its leadership in the industry, commitment to innovation, research and performance, and its perseverance to go above and beyond—achieving New Dietary Ingredient (NDI) status from the FDA for CarnoSyn^® beta-alanine. Over the past year, CarnoSyn^® has gained momentum with its expansion into the healthy aging and wellness sectors, the Japanese marketplace, and its continued efforts with the NFL athletes and Olympic hopefuls on the roster of Team CarnoSyn^®.

CarnoSyn^® beta-alanine is widely-recognized as a patented, high-quality ingredient of choice among companies wishing to use the safest ingredients in their products. NAI has invested millions of dollars of research into CarnoSyn^® over the years and developed a robust portfolio of patents and trademarks to protect its proprietary rights. With the additional exclusivity an NDI notification affords NAI, the company is working diligently with the FDA, CBP, FTC and various other federal and state agencies to ensure compliance and safety by those companies using beta-alanine. Where companies continue to buy and use generic beta-alanine not covered by its NDI, NAI will be alerting the necessary agencies of non-compliance. To the extent such unfair practices also include any infringement of NAI’s intellectual property, these violations will be vigorously pursued.

Daniel Fabricant, Ph.D., President and CEO of NPA, said, “NAI continuously invests and reinvests in science to give consumers confidence in the safety and effectiveness of their ingredient, CarnoSyn. The thing about the right thing, is that it’s always the right thing and NAI embodies that, from the vast number of clinical studies to their recently successful NDI notification, NAI’s work tells a very important story about a brand single minded in the purpose to deliver excellence to the Natural Products consumer.”

“On behalf of our dedicated team at CarnoSyn, our researchers and our supportive consumers, I am honored and humbled to accept this award,” stated Mark LeDoux, NAI’s CEO and Chairman of the Board. “Our commitment to continued investigation using proper scientific discipline is bolstered by this recognition, in our enduring quest to enrich the world with the best of nutrition. As we seek to expand our footprint into a larger demographic segment concerned with sarcopenia and healthy aging, CarnoSyn is leading the way in achieving successful outcomes for people all over the world.”

About CarnoSyn^® Brands:
CarnoSyn^® Brands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn^® instant release beta-alanine and SR CarnoSyn^® sustained release beta-alanine. In 2019, CarnoSyn^® beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status at up to 6.4 grams per day, enabling NAI’s brand partners to provide unique offerings in various food categories. In the sports nutrition segment, both ingredients are well known to deliver benefits for athletic performance: Increased strength, enhanced endurance, faster recovery and greater mental focus.

SR CarnoSyn^® is an advanced delivery form of CarnoSyn^®, which delivers higher dosing levels of beta-alanine, and is proven to provide benefits for both wellness and healthy aging. In 2017, SR CarnoSyn^® was determined to be safe through independent scientific procedures, thus satisfying the technical element of the GRAS determination. The GRAS affirmation allows NAI to broaden their product offerings beyond the sports nutrition space and focus on the dietary supplement and food and beverage industries, including medical and other fortified food products.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

CONTACT:
Renee Michaelson, CarnoSyn^® Marketing Manager, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Websites: http://www.carnosyn.com/ and http://www.srcarnosyn.com/ and http://nai-online.com

Source: PR Newswire

California-based Natural Alternatives International, Inc. (NAI) filed a lawsuit against Vitalize Labs, LLC (doing business as Eboost) for allegedly infringing NAI’s CarnoSyn beta-alanine trademarks. More>